Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361959280> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4361959280 abstract "<div>Abstract<p>Tagraxofusp-erzs (Elzonris, Stemline) is a cytotoxin that targets CD123-expressing cells. On December 21, 2018, FDA approved tagraxofusp-erzs for the treatment of blastic plasmacytoid dendritic cell neoplasms (BPDCN) in adult and pediatric patients 2 years and older. Approval was based on the response rate in a single-arm trial, Study STML-401-0114; the pivotal cohort included 13 patients with treatment-naïve BPDCN who received tagraxofusp-erzs monotherapy. The complete response or clinical complete response (CR/CRc) rate in the pivotal cohort was 54% (95% CI: 25%–81%), and the median duration of CR/CRc was not reached with a median follow-up of 11.5 months (range: 0.2–12.7). In a separate exploratory cohort, a CR/CRc was achieved by 2 (13%) patients with R/R BPDCN. Safety was assessed in 94 patients with myeloid neoplasms treated with tagraxofusp-erzs at the approved dose and schedule. The major toxicity was capillary leak syndrome (CLS), which occurred in 55% of patients and was fatal in 2%. Hepatotoxicity and hypersensitivity reactions were reported in 88% and 46% of patients, respectively. Other common (≥30%) adverse reactions were nausea, fatigue, peripheral edema, pyrexia, and weight increase. A high proportion of patients (85%) developed neutralizing antidrug antibodies. Tagraxofusp-erzs is the first FDA-approved treatment for BPDCN.</p></div>" @default.
- W4361959280 created "2023-04-05" @default.
- W4361959280 creator A5004483141 @default.
- W4361959280 creator A5007273011 @default.
- W4361959280 creator A5009227178 @default.
- W4361959280 creator A5013196129 @default.
- W4361959280 creator A5026362268 @default.
- W4361959280 creator A5028296024 @default.
- W4361959280 creator A5029612220 @default.
- W4361959280 creator A5041458996 @default.
- W4361959280 creator A5046390137 @default.
- W4361959280 creator A5049582745 @default.
- W4361959280 creator A5051520990 @default.
- W4361959280 creator A5066528744 @default.
- W4361959280 creator A5074097054 @default.
- W4361959280 creator A5076377082 @default.
- W4361959280 creator A5078022350 @default.
- W4361959280 creator A5080059584 @default.
- W4361959280 creator A5089125177 @default.
- W4361959280 date "2023-03-31" @default.
- W4361959280 modified "2023-10-14" @default.
- W4361959280 title "Data from FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm" @default.
- W4361959280 doi "https://doi.org/10.1158/1078-0432.c.6529523" @default.
- W4361959280 hasPublicationYear "2023" @default.
- W4361959280 type Work @default.
- W4361959280 citedByCount "0" @default.
- W4361959280 crossrefType "posted-content" @default.
- W4361959280 hasAuthorship W4361959280A5004483141 @default.
- W4361959280 hasAuthorship W4361959280A5007273011 @default.
- W4361959280 hasAuthorship W4361959280A5009227178 @default.
- W4361959280 hasAuthorship W4361959280A5013196129 @default.
- W4361959280 hasAuthorship W4361959280A5026362268 @default.
- W4361959280 hasAuthorship W4361959280A5028296024 @default.
- W4361959280 hasAuthorship W4361959280A5029612220 @default.
- W4361959280 hasAuthorship W4361959280A5041458996 @default.
- W4361959280 hasAuthorship W4361959280A5046390137 @default.
- W4361959280 hasAuthorship W4361959280A5049582745 @default.
- W4361959280 hasAuthorship W4361959280A5051520990 @default.
- W4361959280 hasAuthorship W4361959280A5066528744 @default.
- W4361959280 hasAuthorship W4361959280A5074097054 @default.
- W4361959280 hasAuthorship W4361959280A5076377082 @default.
- W4361959280 hasAuthorship W4361959280A5078022350 @default.
- W4361959280 hasAuthorship W4361959280A5080059584 @default.
- W4361959280 hasAuthorship W4361959280A5089125177 @default.
- W4361959280 hasConcept C126322002 @default.
- W4361959280 hasConcept C197934379 @default.
- W4361959280 hasConcept C2777482430 @default.
- W4361959280 hasConcept C2779282312 @default.
- W4361959280 hasConcept C2780580376 @default.
- W4361959280 hasConcept C29730261 @default.
- W4361959280 hasConcept C71924100 @default.
- W4361959280 hasConcept C72563966 @default.
- W4361959280 hasConcept C90924648 @default.
- W4361959280 hasConceptScore W4361959280C126322002 @default.
- W4361959280 hasConceptScore W4361959280C197934379 @default.
- W4361959280 hasConceptScore W4361959280C2777482430 @default.
- W4361959280 hasConceptScore W4361959280C2779282312 @default.
- W4361959280 hasConceptScore W4361959280C2780580376 @default.
- W4361959280 hasConceptScore W4361959280C29730261 @default.
- W4361959280 hasConceptScore W4361959280C71924100 @default.
- W4361959280 hasConceptScore W4361959280C72563966 @default.
- W4361959280 hasConceptScore W4361959280C90924648 @default.
- W4361959280 hasLocation W43619592801 @default.
- W4361959280 hasOpenAccess W4361959280 @default.
- W4361959280 hasPrimaryLocation W43619592801 @default.
- W4361959280 hasRelatedWork W2035049801 @default.
- W4361959280 hasRelatedWork W2083653180 @default.
- W4361959280 hasRelatedWork W2315085516 @default.
- W4361959280 hasRelatedWork W2363890076 @default.
- W4361959280 hasRelatedWork W2385187910 @default.
- W4361959280 hasRelatedWork W2603773853 @default.
- W4361959280 hasRelatedWork W2893772422 @default.
- W4361959280 hasRelatedWork W2912652559 @default.
- W4361959280 hasRelatedWork W3120865475 @default.
- W4361959280 hasRelatedWork W4297311873 @default.
- W4361959280 isParatext "false" @default.
- W4361959280 isRetracted "false" @default.
- W4361959280 workType "article" @default.